The Development of Nonthermal Plasma and Tirapazamine as a Novel Combination Therapy to Treat Melanoma In Situ

The Development of Nonthermal Plasma and Tirapazamine as a Novel Combination Therapy to Treat Melanoma In Situ

Although melanoma accounts for only 5.3% of skin cancer, it results in >75% of skin-cancer-related deaths. To avoid disfiguring surgeries on the head and neck associated with surgical excision, there is a clear unmet need for other strategies to selectively remove cutaneous melanoma lesions. Mohs...

Full description

Bibliographic Details
Main Authors: Matthew Yehl, Dominik Kucharski, Michelle Eubank, Brandon Gulledge, Gamal Rayan, Md Gias Uddin, Genevieve Remmers, Eugene S. Kandel, Douglas P. DuFaux, Timothy C. Hutcherson, Sandra Sexton, Shoshanna N. Zucker
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Cells
Subjects:
nonthermal plasma
tirapazamine
medical device
melanoma
skin cancer
gap junctions
Online Access:https://www.mdpi.com/2073-4409/12/16/2113

Similar Items

Similar Items